Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2008-003396-52-FR
EUCTR2008-003396-52-FR
Active, not recruiting
Phase 1

Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.

European Organisation for Research and Treatment of Cancer0 sites626 target enrollmentSeptember 27, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCervical carcinoma (including squamous cell carcinoma, adenosquamous cell or adenocarcinomaMedDRA version: 12.0Level: LLTClassification code 10008242Term: Cervical carcinoma stage IBMedDRA version: 12.0Level: LLTClassification code 10008244Term: Cervical carcinoma stage IIAMedDRA version: 12.0Level: LLTClassification code 10008245Term: Cervical carcinoma stage IIB

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Cervical carcinoma (including squamous cell carcinoma, adenosquamous cell or adenocarcinoma
Sponsor
European Organisation for Research and Treatment of Cancer
Enrollment
626
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 27, 2010
End Date
November 29, 2019
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
European Organisation for Research and Treatment of Cancer

Eligibility Criteria

Inclusion Criteria

  • •\- Cervical carcinoma of following histological types: squamous cell carcinoma, adenosquamous cell or adenocarcinoma
  • •\- FIGO stage Ib2, IIa \>4cm or IIb
  • •\- WHO performance status of 0\-2
  • •\- 18 \- 75 years
  • •\- ANC \> 1\.5 x 109/l, platelets \> 100 x 109/l, bilirubin \< 25 µmol/l or \< 1\.46 mg/dl, creatinine clearance (calculated or measured) \> 60 ml/min
  • •\- Before patient randomization, written informed consent must be given according to ICH/GCP and national/local regulations.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- Small cell, clear cell and other rare variants of the classical adenocarcinoma
  • •\- prior irradiation or chemotherapy
  • •\- previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin
  • •\- any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow\-up schedule; those conditions should be discussed with the patient before registration in the trial
  • •\- pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.Cervical carcinoma (including squamous cell carcinoma, adenosquamous cell or adenocarcinomaMedDRA version: 16.0Level: LLTClassification code 10008242Term: Cervical carcinoma stage IBSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10008244Term: Cervical carcinoma stage IIASystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10008245Term: Cervical carcinoma stage IIBSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2008-003396-52-GBEuropean Organisation for Research and Treatment of Cancer686
Active, not recruiting
Phase 1
A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma
EUCTR2019-003543-30-ITEORTC AISBL/IVZW250
Active, not recruiting
Phase 1
A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcomaPrimary high risk leiomyosarcoma or Liposarcoma ofretroperitoneal space or infra-peritoneal spaces of pelvisMedDRA version: 20.0Level: PTClassification code 10073135Term: Dedifferentiated liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10024189Term: LeiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-003543-30-FREuropean Organisation for Research and Treatment of Cancer250
Active, not recruiting
Phase 1
A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma
EUCTR2019-003543-30-CZEuropean Organisation for Research and Treatment of Cancer250
Active, not recruiting
Phase 1
A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcomaPrimary high risk leiomyosarcoma or Liposarcoma ofretroperitoneal space or infra-peritoneal spaces of pelvisMedDRA version: 20.0Level: PTClassification code 10073135Term: Dedifferentiated liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10024189Term: LeiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-003543-30-SKEuropean Organisation for Research and Treatment of Cancer250